Genomics Cancer Clinical Trials Initiative National Technical Service

⁠⁠⁠This procurement seeks to contract a provider for the services of a Genomics Cancer Clinical Trials Initiative (GCCTI) National Technical Service that will assist Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) supported by Cancer Australia through the Support for Cancer Clinical Trials program, to develop cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types.

The service provider, as Cancer Australia’s GCCTI National Technical Service, will be required to provide, its technical services from 1 August 2018 - 30 June 2021. The GCCTI will be required to develop cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types. A minimum of one cancer clinical trial protocol per annum will be developed in consultation with the CTGs supported by Cancer Australia and other key stakeholders, to the point of completion and submission of a competitive grant application.

In achieving this requirement the technical services provided will include, but are not limited to, the following minimum services:
* Developing an engagement strategy to involve CTGs and other relevant stakeholders in the scoping and development of cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types;
* Conducting workshops with all CTGs and key stakeholders to identify potential molecular targets for the cancer clinical trial protocols;
* Developing and writing cancer clinical trial protocols that that specifically target cancer mutations/ molecular markers across a range of tumour types (including literature reviews, reviews of international cancer mutation/ molecular marker clinical trial protocols, peer review of protocols, statistical design, sample size calculations);
* Writing grant applications for the funding of the cancer clinical trials developed (including preparation of budgets). Grant applications must remain competitive and responsive to the changing requirements of competitive funders of cancer clinical trials.